Despite the substantial benefits of bariatric metabolic surgery in reducing body mass index (BMI) and improving comorbid conditions such as diabetes mellitus (DM), hypertension (HTN), and hyperlipidemia (HLP), WR, IWL, and other complications can hinder long-term success [4,5,6,7]
It is not insulin and should not replace insulin for people who need insulin therapy
Eli Lillys triple agonist, retatrutide, demonstrated an average weight loss of 16.8% in a Phase 3 trial for the treatment of type 2 diabetes, the company announced today
GLP-1 drugs, especially injectable versions, can sometimes cause local irritation at the injection site, such as skin discoloration or swelling
The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability resulting in approximately three times greater potency than IGF-1, with a significantly longer half-life of about 2030 hours relative to IGF-1s half-life of about 1215 hours
